Bovine Chymotrypsin (Bos taurus)

Bovine chymotrypsin is a serine protease derived from Bos taurus pancreatic tissue that cleaves peptide bonds on the carboxyl side of aromatic and large hydrophobic amino acids including phenylalanine, tyrosine, and tryptophan. It functions via a catalytic triad (Ser195, His57, Asp102) to hydrolyze dietary proteins and has been studied for its role in pancreatitis models and milk protein digestion.

Origin & History

Bovine chymotrypsin is a serine protease enzyme extracted from the pancreas of cattle (Bos taurus), typically activated from its inactive precursor chymotrypsinogen through proteolytic cleavage. It belongs to the endopeptidase class of enzymes, specifically hydrolyzing peptide bonds adjacent to aromatic amino acids like phenylalanine, tyrosine, and tryptophan.

Historical & Cultural Context

No evidence of bovine chymotrypsin use in traditional medicine systems such as Ayurveda or Traditional Chinese Medicine was found. Its study and application are confined to modern biochemistry as a digestive enzyme.

Health Benefits

• Protein digestion support - cleaves peptide bonds with high selectivity for aromatic residues (in vitro evidence only)
• May protect against pancreatitis severity by degrading trypsinogen (animal model evidence only)
• Assists in breaking down milk proteins including α-lactalbumin, β-lactoglobulin, and β-casein (in vitro evidence only)
• Natural digestive enzyme replacement for pancreatic insufficiency (theoretical benefit, no clinical evidence)
• Potential anti-inflammatory effects through protein breakdown (no direct clinical evidence)

How It Works

Bovine chymotrypsin operates through a catalytic triad composed of serine-195, histidine-57, and aspartate-102, which facilitates nucleophilic attack on peptide bonds adjacent to aromatic residues (phenylalanine, tyrosine, tryptophan) and large hydrophobic residues (leucine, methionine). The enzyme forms an acyl-enzyme intermediate with the substrate before hydrolysis releases the cleaved peptide fragment and regenerates the active site. In pancreatic physiology, chymotrypsin also degrades trypsinogen, a proposed protective mechanism against premature protease activation and pancreatitis progression observed in animal models.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses examining bovine chymotrypsin as a dietary supplement were identified. Research is limited to in vitro enzymatic assays showing hydrolysis of milk proteins and animal models (CTRB1-deficient mice) demonstrating protective effects against cerulein-induced pancreatitis severity.

Clinical Summary

Human clinical evidence for supplemental bovine chymotrypsin is limited, with most mechanistic data derived from in vitro enzyme kinetics and rodent studies. Animal model research has demonstrated that chymotrypsin-mediated degradation of trypsinogen can reduce severity markers of acute pancreatitis, though these findings have not been replicated in controlled human trials. In vitro studies confirm robust hydrolytic activity against milk proteins including α-lactalbumin and β-lactoglobulin, suggesting a potential role in dairy protein digestibility, but no large-scale randomized controlled trials (RCTs) with quantified clinical endpoints in humans have been published. The overall evidence quality is low-to-moderate, and claims beyond enzymatic mechanism remain preliminary.

Nutritional Profile

Bovine chymotrypsin is a purified enzymatic protein derived from bovine pancreatic tissue, not a nutritional food ingredient. As a refined enzyme preparation, it contains negligible macronutrients in functional dosage forms. Protein content: chymotrypsin itself is a serine protease protein of approximately 25 kDa molecular weight, composed of 241 amino acids (three polypeptide chains A, B, C linked by disulfide bonds); at typical supplemental doses of 1–10 mg per serving, direct amino acid contribution is nutritionally insignificant. Carbohydrate content: essentially zero in purified form. Fat content: essentially zero in purified form. Micronutrients: no meaningful vitamin or mineral content inherent to the purified enzyme itself; however, the active site contains a catalytic triad of serine (Ser195), histidine (His57), and aspartate (Asp102) residues critical to function. Bioactive compounds: the primary bioactive is the enzyme itself, standardized by activity units (typically expressed as USP units or NF units; commercial preparations commonly range from 1,000–100,000 NF units per gram). Calcium dependency: chymotrypsin stability is enhanced by calcium ions, which maintain structural integrity of the enzyme at physiological temperatures. Bioavailability note: oral bioavailability of intact enzymatic activity is substantially limited by gastric acid denaturation and pepsin degradation; enteric coating or buffered formulations are required to preserve measurable activity reaching the small intestine; some evidence suggests partial absorption of peptide fragments but intact enzyme systemic absorption is minimal.

Preparation & Dosage

No clinically studied dosage ranges for bovine chymotrypsin supplements are available. Research uses in vitro enzymatic assays (28 mM peptide bonds/s/mM enzyme) rather than human dosing studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Pancreatin, Bromelain, Papain, Betaine HCl, Ox Bile

Safety & Interactions

Bovine chymotrypsin is generally considered low-risk when taken orally, as gastric acid and intestinal conditions denature much of the protein before systemic absorption, though individuals with known beef or bovine-derived product allergies should avoid it. Topical or ophthalmic formulations of chymotrypsin (used historically in cataract surgery) carry risks of uveitis and increased intraocular pressure, which are not applicable to oral supplemental use. Potential drug interactions include enhanced absorption or degradation of co-administered protein-based drugs or peptide hormones, and concurrent use with anticoagulants warrants caution given theoretical protease effects on clotting factor proteins. Safety data in pregnant or breastfeeding women is insufficient, and use in these populations is not recommended without medical supervision.